Angiotensin II Type 2‐Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain

Neuropathic pain is a large unmet medical need. The angiotensin II type 2 (AT 2 ) receptor is a target with promising data in rodent models of peripheral neuropathic pain.[1][Smith, M.T., 2013], [2][Smith, M.T., 2013], [3][Muralidharan, A., 2014], [4][Smith, M.T., 2014] The AT 2 receptor has attracted attention on the basis of human data from a proof‐of‐concept clinical trial showing that oral EMA401, a highly selective, peripherally restricted, small molecule AT 2 receptor antagonist, at 100 mg twice‐daily for 4 weeks, alleviated postherpetic neuralgia,[5][Rice, A.S., 2014] an often intractable type of peripheral neuropathic pain.